CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia

	CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia
	Yi B 1,2; Zhang Z 1,2; Zhang M 1,2; Schwartz-Albiez R 3; Cao Y[*]1
刊名	ONCOLOGY REPORTS
	2013
卷号	30 期号:4 页码:1841-1847
关键词	CD176 Thomsen-Friedenreich antigen antibody leukemia immunotherapy mouse
通讯作者	caoy@mail.kiz.ac.cn
合作状况	其它
英文摘要	CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate structure. CD176 is expressed at the surface of human leukemic cells but is almost absent in normal and benign adult human tissues. Therefore, CD176 could be a promising target for antitumor immunotherapy. In the present study, pre-immunization with asialoglycophorin A (containing the CD176 oligosaccharide chains) was able to significantly improve the survival time of mice carrying CD176(+) leukemia as compared to the control mice without the immunization. Furthermore, the passive transfer of CD176 antiserum which reacted only with the tumor-associated CD176 in cancer cells, was able to effectively prolong the survival time of CD176(+) leukemia mice. In particular, the CD176 antiserum treatment could inhibit the growth and spreading of CD176(+) leukemic cells in bone marrow, spleen, liver, and lung as evidenced by histopathological examination. CD176 antiserum could induce the apoptosis of CD176(+) leukemic cells in vivo in a manner as previously observed in vitro. The data provided strong evidence that both CD176 antigen-based active immunotherapy and CD176 antibody-based passive immunotherapy lead to a therapeutic response in CD176(+) leukemia mice. Therefore, both CD176 vaccine and CD176 antibody drug may be beneficial for the treatment of CD176(+) leukemia patients.
收录类别	SCI
资助信息	The present study was financially supported by grants from the National Natural Science Foundation of China (no. 81072563), the Yunnan Province Science and Technology Department (2008CCO15, 2011CI139) and the Chinese Academy of Sciences (KSCX2-YW-R-196).
语种	英语
WOS记录号	WOS:000324539700040
公开日期	2014-09-26
内容类型	期刊论文
源URL	[http://159.226.149.42:8088/handle/152453/8008]
专题	昆明动物研究所_分子病理学
作者单位	1.Laboratory of Molecular and Experimental Pathology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunna 2.Graduate University of the Chinese Academy of Sciences, Beijing, P.R. Chin 3.Translational Immunology Unit, German Cancer Research Center, Heidelberg, Germany
推荐引用方式 GB/T 7714	Yi B,Zhang Z,Zhang M,et al. CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia[J]. ONCOLOGY REPORTS,2013,30(4):1841-1847.
APA	Yi B,Zhang Z,Zhang M,Schwartz-Albiez R,&Cao Y[*].(2013).CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia.ONCOLOGY REPORTS,30(4),1841-1847.
MLA	Yi B,et al."CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia".ONCOLOGY REPORTS 30.4(2013):1841-1847.